If you are wondering whether Krystal Biotech's share price still lines up with its underlying value, you are not alone. A closer look at its valuation can help frame that question more clearly. The ...

Krystal Biotech KRYS reported fourth-quarter 2025 earnings per share (EPS) of $1.70, which surpassed the Zacks Consensus ...

Q VYJUVEK revenue and $730.3 million since U.S. launchFDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast ...

Krystal has released an improved Crispy Fish Slider in time for Lent, and is debuting Krush'd Sodas, a $1 upgrade that ...

Krystal Biotech (NasdaqGS:KRYS) received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707 in advanced ...

Analysts estimate that Krystal Biotech will report an earnings per share (EPS) of $1.61. Krystal Biotech bulls will hope to hear the company announce they've not only beaten that estimate, but also to ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript February 17, 2026 Krystal Biotech, Inc. beats earnings ...

"In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to ...

A Southern burger chain known for its miniature sliders will make its Northeast debut in collaboration with a former New York ...

The FDA’s decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with ...

With seafood top of mind during Lent and “dirty soda” flavors gaining momentum nationwide, Krystal is turning spring cravings ...